ASSESSMENT OF PREVALENCE OF BREAST CANCER IN PATIENTS WITH OBESITY AND EVALUATING BENEFITS OF STATIN THERAPY IN BREAST CANCER TREATMENT
DOI:
https://doi.org/10.22159/ajpcr.2025v18i5.54356Keywords:
Breast Cancer, prevalence, statins, Body Mass Index, Invasive Ductal Carcinoma, Atorvastatin, Rosuvastatin, RecurrenceAbstract
ABSTRACT
Objective: Assessing the prevalence of breast cancer and evaluating the feasibility of statins as adjunct therapy in breast cancer management as well as their effectiveness in reducing recurrence.
Methods: A bi-directional study was conducted over 6 months at Parul Sevashram Hospital, India, involving 102 breast cancer patients. Data on demographics, body mass index (BMI), cancer subtypes, statin usage (type, dose, duration), adjuvant therapy integration, and recurrence were collected through medical records and organized discussions. Analytical methods comprised of Pearson-Chi square tests to assess associations between statin continuation and recurrence.
Results: Among 102 patients, 46.07% (n=47) possessed a normal BMI, whereas 53.66% (n=55) were pre-obese/obese (BMI≥25). Invasive ductal carcinoma (65%, n=63) was the most prevalent subtype. Of 83 patients assessed for statin use, 38.55% (n=32) were prescribed statins (atorvastatin: 62.5%, rosuvastatin: 31.25%, simvastatin: 6.25%), primarily for hypercholesterolemia (71.87% obese patients). Among statin users, 71.87% (n=23) continued therapy as adjuvant treatment. Recurrence occurred in 21.74% (n=5) of statin-continuation patients versus 66.67% (n=6) in the discontinuation group (χ²=3.97, p=0.046). Lipophilic statins (atorvastatin, simvastatin) showed stronger recurrence reduction (78.26% non-recurrence) compared to discontinuation (33.33%).
Conclusion: Statin continuation as adjuvant therapy significantly reduced breast cancer recurrence, particularly in obese patients, with lipophilic statins (e.g., atorvastatin) demonstrating notable efficacy. The study highlights statins’ potential dual role in managing hyperlipidemia and cancer outcomes, emphasizing their integration into breast cancer care for high-BMI populations. Further large-scale trials are needed to validate optimal dosing, duration, and long-term survival benefits.
Downloads
References
Gajbhiye SA, Patil MP. Solid lipid nanoparticles: A review on different techniques and approaches to treat breast cancer. Int J App Pharm. 2023 Mar 7;15(2):52-62. doi: 10.22159/ijap.2023v15i2.46970
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 22;149(4):778-89. doi: 10.1002/ijc.33588, PMID: 33818764
Gokul Raj R, Preethi S, Patil AB, Jain V, Ajmeer R. A review of advanced nanotechnologies and drug delivery systems of salinomycin and their role in triple-negative breast cancer. Int J App Pharm. 2022 Jul 7;14(4):103-14. doi: 10.22159/ijap.2022v14i4.44237
Dwivedi U, Jain A, Ali FB, Ali M. Evaluation of serum and salivary ca-125 in breast cancer patients - An analytical study. Asian J Pharm Clin Res. 2023 Apr 7;16(4):97-9.
Devi TS, Devi G, Gunasekaran S. Spectroscopic and statistical analysis on cancerous human breast tissues. Int J Chem Res. 2010 Jan 1;1(1):9-17.
Preethi S, Kumar H, Rawal VB, Ajmeer R, Jain V. Overview of mitoxantrone-a potential candidate for treatment of breast cancer. Int J Appl Pharm. 2022 Mar 7;14(2):10-22.
Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005 Dec 1;23(34):8606-12. doi: 10.1200/JCO.2005.02.7045, PMID: 16260694
Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998 Jan 1;19(1):26-37. doi: 10.1016/s0165- 6147(97)01147-4, PMID: 9509899
Beck P, Wysowski DK, Downey W, Butler-Jones D. Statin use and the risk of breast cancer. J Clin Epidemiol. 2003 Mar;56(3):280-5. doi: 10.1016/s0895-4356(02)00614-5, PMID: 12725884
David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, et al. TGF-β tumor suppression through a lethal EMT. Cell. 2016 Feb;164(5):1015-30. doi: 10.1016/j.cell.2016.01.009, PMID: 26898331
Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP. Statins and breast cancer prognosis: Evidence and opportunities. Lancet Oncol. 2014 Sep;15(10):e461-8. doi: 10.1016/S1470-2045(14)70119-6, PMID: 25186049
Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, et al. Regulation of the hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012 Aug;150(4):780-91. doi: 10.1016/j. cell.2012.06.037, PMID: 22863277
Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez- Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012 Jan;148(1-2):244-58. doi: 10.1016/j.cell.2011.12.017, PMID: 22265415
Di Bello E, Zwergel C, Mai A, Valente S. The innovative potential of statins in cancer: New targets for new therapies. Front Chem. 2020 Jun 18;8:516. doi: 10.3389/fchem.2020.00516, PMID: 32626692
Baek AE, Yu YR, He S, Wardell SE, Chang CY, Kwon S, et al. The cholesterol metabolite 27 hydroxycholesterol facilitatesbreast cancer metastasis through its actions on immune cells. Nat Commun. 2017 Oct 11;8(1):864. doi: 10.1038/s41467-017-00910-z, PMID: 29021522
Beckwitt CH, Clark AM, Ma B, Whaley D, Oltvai ZN, Wells A. Statins attenuate outgrowth of breast cancer metastases. Br J Cancer. 2018 Oct;119(9):1094-105. doi: 10.1038/s41416-018-0267-7, PMID: 30401978
Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res. 1980 Jul;21(5):505-17. doi: 10.1016/ S0022-2275(20)42221-7, PMID: 6995544
Sakellakis M, Akinosoglou K, Kostaki A, Spyropoulou D, Koutras A. Statins and risk of breast cancer recurrence. Breast Cancer (Dove Med Press). 2016 Nov;8:199-205. doi: 10.2147/BCTT.S116694, PMID: 27853392
Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 2012;40(4):935-41. doi: 10.3892/ ijo.2011.1273, PMID: 22134829
Kotamraju S, Williams CL, Kalyanaraman B. Statin-induced breast cancer cell death: Role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 2007 Aug 1;67(15):7386-94. doi: 10.1158/0008- 5472.CAN-07-0993, PMID: 17671209
Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002 Apr 5;90(6):737-44. doi: 10.1161/01.res.0000014081.30867.f8, PMID: 11934843
Bhosale RR, Janugade BU, Chavan DD, Thorat VM. Current perspectives on applications of nanoparticles for cancer management. Int J Pharm Pharm Sci. 2023 Nov 1;15(11):1-10. doi: 10.22159/ ijpps.2023v15i11.49319
Mehdi S, Chauhan A, Dhutty A. Cancer and new prospective to treat cancer. Int J Curr Pharm Sci. 2023 Nov 15;15(6):16-22. doi: 10.22159/ ijcpr.2023v15i6.3078
Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 2023 Jan 12;15(2):485. doi: 10.3390/ cancers15020485, PMID: 36672434
Dorsch M, Kowalczyk M, Planque M, Heilmann G, Urban S, Dujardin P, et al. Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. Cell Rep. 2021 Nov 23;37(8):110056. doi: 10.1016/j.celrep.2021.110056, PMID: 34818551
Published
How to Cite
Issue
Section
Copyright (c) 2025 Zainab Lokhandwala, Fahim Khan, Dr. SP Srinivas Nayak, Dr. Gunosindhu Chakraborthy
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
